Micellic assemblies

Patent metadata

Field	Value
Publication number	US-9662403-B2
Application number	US-201615059026-A
Country	US
Kind code	B2
Filing date	Mar 2, 2016
Priority date	May 13, 2008
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A micelle comprising a core and a shell, the micelle comprising a plurality of block copolymers of Formula I:

wherein
A 0 , A 1 , A z , A 3 , and A 4 are independently selected from the group consisting of —C—C—, —C(O)(C) a C(O)O—, and —O(C) a C(O)—, wherein a is 1-4;
Y 4 is selected from the group consisting of hydrogen, -(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl, —C(O)O(1C-10C)alkyl, -(4C-10C)heteroaryl, and -(6C-10C)aryl, any of which is optionally substituted with one or more fluorine groups;
Y 0 , Y 1 , and Y 2 are independently selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C)alkyl-, —OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, —C(O)NR 6 (2C-10C)alkyl-, -(4C-10C)heteroaryl- , and -(6C-10C)aryl-;
Y 3 is selected from the group consisting of a covalent bond, -(1C-10C)alkyl-, -(4C-10C)heteroaryl-, and -(6C-10C)aryl-; wherein tetravalent carbon atoms of A 0 -A 4 that are not fully substituted with R 1 -R 5 and Y 0 -Y 4 are completed with an appropriate number of hydrogen atoms;
R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of hydrogen, —CN, alkyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, any of which may be optionally substituted with one or more fluorine atoms;
Q 0 is a residue selected from the group consisting of residues which are hydrophilic at physiologic pH; conjugatable or functionalizable residues; and hydrogen;
Q 1 is a residue which is hydrophilic at normal physiological pH;
Q 2 is a residue which is positively charged at normal physiological pH;
Q 3 is a residue which is negatively charged at normal physiological pH, but undergoes protonation at lower pH;
m is a mole fraction of 0 to less than 1.0;
n is a mole fraction of greater than 0 to 1.0; wherein m+n=1;
p is a mole fraction of 0.1 to 0.9;
q is a mole fraction of 0.1 to 0.9;
r is present up to a mole fraction of 0.8; wherein p+q+r=1;
v is from 1 to 25 kDa; and
w is from 1 to 50 kDa.

2. The micelle of claim 1 , wherein each of A 0 , A 1 , A 2 , A 3 , and A 4 is —C—C—.

3. The micelle of claim 1 , wherein m is a mole fraction of 0 to 0.49.

4. The micelle of claim 2 , wherein m is a mole fraction of 0 to 0.49.

5. The micelle of claim 1 , wherein p is a mole fraction of 0.2 to 0.5.

6. The micelle of claim 2 , wherein p is a mole fraction of 0.2 to 0.5.

7. The micelle of claim 1 , wherein p and q are within 0.3 of each other.

8. The micelle of claim 2 , wherein p and q are within 0.3 of each other.

9. The micelle of claim 1 , wherein w is from 5 to 50 kDa.

10. The micelle of claim 2 , wherein w is from 5 to 50 kDa.

11. The micelle of claim 1 , wherein the ratio of w to v is from 5:1 to 1:1.

12. The micelle of claim 2 , wherein the ratio of w to v is from 5:1 to 1:1.

13. The micelle of claim 1 , wherein Q 0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q 1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q 2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q 3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

14. The micelle of claim 2 , wherein Q 0 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, thiol, azide, alkyne, succinimide ester, tetrafluorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, pyridyl disulfide, and hydrogen;
Q 1 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, pyridyl, carboxyl, sulfonamide, boronate, phosphonate, phosphate, hydroxy, polyoxylated alkyl, polyethylene glycol, polypropylene glycol, and thiol;
Q 2 is a residue selected from the group consisting of amino, alkylamino, ammonium, alkylammonium, guanidine, imidazolyl, and pyridyl; and
Q 3 is a residue selected from the group consisting of carboxyl, boronate, phosphonate, and phosphate.

15. The micelle of claim 1 , wherein the micelle comprises a targeting moiety.

16. The micelle of claim 15 , wherein the targeting moiety binds to the asialoglycoprotein receptor.

17. The micelle of claim 2 , wherein the micelle comprises a targeting moiety.

18. The micelle of claim 17 , wherein the targeting moiety binds to the asialoglycoprotein receptor.

19. The micelle of claim 1 , wherein the micelle has an average hydrodynamic diameter of 10 nm to 100 nm.

20. The micelle of claim 2 , wherein the micelle has an average hydrodynamic diameter of 10 nm to 100 nm.

Assignees

• Univ Washington
• Phaserx Inc

Inventors

• Stayton Patrick S
• Hoffman Allan S
• Convertine Anthony
• Duvall Craig L
• Benoit Danielle
• Overell Robert
• Johnson Paul H
• Gall Anna S
• Prieve Mary G
• Paschal Amber E E
• Diab Charbel
• De Priyadarsi

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title